InClinica

InClinica provides specialized clinical research and development services aimed at the pharmaceutical and biotechnology sectors, facilitating efficient clinical trial management and compliance solutions. InClinica, founded in 2016, is based in Wayne, US, and focuses on offering clinical research services. The company was acquired by Velocity Fund Management in August 2016, although financial terms were not disclosed. The CEO, James Nolan, leads the firm which has completed one deal to date.

Inclinica. com primarily focuses on offering advanced clinical research and development services tailored for the pharmaceutical and biotechnology sectors. Their core product offerings include a comprehensive suite of clinical trial management services, which facilitate the design, implementation, and monitoring of clinical trials. These services aim to address critical challenges in drug development, such as reducing time to market and enhancing patient recruitment.

Inclinica serves a diverse client base, including pharmaceutical companies, biotech firms, and research institutions, all of whom rely on these services to navigate complex regulatory landscapes and ensure compliance throughout the trial process. The company operates across multiple geographical markets, including North America, Europe, and select regions in Asia, providing tailored solutions that cater to the unique requirements of clients in these areas. Inclinica generates revenue through a combination of service contracts and partnerships with its clients in the pharmaceutical and biotechnology industries. The revenue model is predominantly B2B, involving direct service agreements where clients pay for specific clinical trial management services.

These transactions typically include project-based pricing structures, where clients are billed based on the scope and complexity of the services rendered during the trial phases. Inclinica's flagship services may encompass tailored clinical trial designs, patient recruitment strategies, and regulatory compliance assistance, all integral to the successful execution of clinical trials. The company’s revenue is aligned with the successful deployment of these services, reflecting the critical nature of their offerings in the drug development process. InClinica aims to enhance its service offerings with the introduction of new products specifically designed for improved clinical trial efficiency.

The company plans to expand its presence in new geographical markets, particularly targeting additional regions in Asia by 2025. The funding from the acquisition by Velocity Fund Management will support these initiatives, aiding in the development of innovative solutions and the expansion into these strategic markets.